Ranked #218 on the list Best Patient Health Record of All Time

Based on 0 votes

About Gadobutrol

  • Subjects:
  • Subject of:

Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA). It received marketing approval in Canada and in the United States. As of 2007, it was the only GBCA approved at 1.0 molar concentrations. Gadobutrol is marketed by Bayer Schering Pharma as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist.

Comment on Gadobutrol


There are no voters yet.